Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




How Well can we Compare Different Biologic Agents for RA?
Link ID 27605
Title How Well can we Compare Different Biologic Agents for RA?
Url http://www.medscape.com/viewarticle/725863?src=rss
Description What are the best biologic agents available for rheumatoid arthritis? This study takes a look. Nature Reviews Rheumatology
Category Articles > Rheumatology
Keywords
Date Aug 7, 2010
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Rheumatology
1. Systemic Lupus Erythematosus Patients Exhibit Functional Deficiencies of Endothelial Progenitor Cell
  Endothelial progenitor cells (EPCs) are described to serve as a biomarker for CV risk. Since CV risk is seen in Systemic lupus erythematosus (SLE), would SLE be associated with altered EPC levels?
Rheumatology
Category:   Articles > Rheumatology


2. Ankle Pain With Swelling and Stiffness: Short and Long-term Treatment
  Patient presented with bilateral ankle swelling, pain, and stiffness. Recommendations for short- and long-term treatment are presented by Stanley Cohen, MD.
Medscape Rheumatology
Category:   Articles > Rheumatology


3. Guiding RA Patients Through Medicare Maze Toward Payment for Biologic Therapies
  Dr. Kevin Deane comments on a study that explores the complicated cost structure of Medicare plans and coverage of biologic therapies used by patients with rheumatoid arthritis. Medscape Rheumatology
Category:   Articles > Rheumatology


4. Unusual Clinical Presentations of Gout
  Gout can cause diagnostic dilemmas that can impact patient treatment and care, as these case reports show. Current Opinion in Rheumatology
Category:   Articles > Rheumatology


5. Rituximab Slows Joint Damage in Rheumatoid Arthritis
  Rituximab inhibits joint damage progression in rheumatoid arthritis (RA) patients who have an inadequate response to tumor necrosis factor (TNF) inhibitor therapies, according to a report in the January issue of the Annals of the Rheumatic Diseases. Reuters Health Information
Category:   Articles > Rheumatology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS